Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.

Eros Papademetriou,Xing Liu,Amélie Beaudet,Yuen Tsang,Ravi Potluri,Sumeet Panjabi

Journal of medical economics（2023）

引用 0|浏览2

暂无评分

摘要

Compared to oral and inhaled treprostinil, oral selexipag may incur lower medical costs and reduce PAH related outpatient visits for patients with PAH.

查看译文

关键词

I,I1,I10,I11,claims data,healthcare resource utilization,medical costs,prostacyclin pathway agents,pulmonary arterial hypertension,selexipag,treprostinil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要